Slingshot Insights | Arql Overview

ARQL Overview

Upcoming Projects (ARQL)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (ARQL)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (ARQL)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (ARQL)

Preclinical data released on ARQ 531 Reversible BTK Inhibitor in Ibrutinib Resistant CLL and Richter's Transformation
Ticker: ARQL
Occurred on: Aug 09, 2018
FDA Clears ArQule's (ARQL) Phase 1 Trial of ARQ 531 in Patients with B-Cell Malignancies
Ticker: ARQL
Occurred on: Apr 11, 2017
Tivantinib - METIV-HCC phase 3 trial in hepatocellular carcinoma is scheduled to conclude by year-end 2016 or early 2017. Top-line data is expected according to that timeline.
Ticker: ARQL
Occurred on: Feb 17, 2017
Data on Proprietary BTK Inhibitor, ARQ 531, Demonstrating Inhibition of Wild Type and C481S Mutant BTK and Superiority to Ibrutinib in TCL1 Mouse Model Presented at the American Society of Hematology Annual Meeting
Ticker: ARQL
Occurred on: Dec 04, 2016
ArQule Presents Preclinical Data for ARQ 531, a Proprietary Reversible Inhibitor of Wild Type and Mutant BTK, at the 2016 Pan Pacific Lymphoma Conference
Ticker: ARQL
Occurred on: Jul 18, 2016
Phase 3 interim data analysis for tivantinib to take place during the first half of 2016
Ticker: ARQL
Occurred on: Mar 22, 2016

Strategic Initiatives (ARQL)

Merk (MRK) is set to acquire ArQule (ARQL) at $20 per share in cash for an approximate total equity value of $2.7 billion
Tickers: ARQL, MRK
Announcement Date: Dec 09, 2019